FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.10  |  FHIR Version n/a  User: [n/a]

773881003: Antiparkinson therapeutic role (role)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 31-Jan 2019. Module: SNOMED CT core module

Descriptions:

Id Description Lang Type Status Case? Module
3726863016 Antiparkinson therapeutic role en Synonym Active Entire term case insensitive SNOMED CT core module
3726864010 Antiparkinson therapeutic role (role) en Fully specified name Active Entire term case insensitive SNOMED CT core module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Antiparkinson therapeutic role Is a Therapeutic role true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Medicinal product acting as antiparkinson agent (product) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing levodopa Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing tolcapone Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing pergolide Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing pramipexole Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing ropinirole Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing cabergoline Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing entacapone Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing bromocriptine Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing trihexyphenidyl Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing lisuride Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely levodopa 500 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely amantadine hydrochloride 100 milligram/1 each conventional release oral capsule Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely selegiline hydrochloride 1.25 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely selegiline hydrochloride 10 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely selegiline hydrochloride 5 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ropinirole (as ropinirole hydrochloride) 250 microgram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ropinirole (as ropinirole hydrochloride) 1 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ropinirole (as ropinirole hydrochloride) 2 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ropinirole (as ropinirole hydrochloride) 5 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely cabergoline 1 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely cabergoline 2 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely cabergoline 4 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely entacapone 200 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole dihydrochloride 88 microgram/1 each conventional release oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole dihydrochloride 180 microgram/1 each conventional release oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole dihydrochloride 700 microgram/1 each conventional release oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely trihexyphenidyl hydrochloride 2 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely trihexyphenidyl hydrochloride 5 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely orphenadrine hydrochloride 5 milligram/1 milliliter conventional release oral solution Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely benzatropine mesilate 2 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely biperiden hydrochloride 2 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely procyclidine hydrochloride 5 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely bromocriptine (as bromocriptine mesilate) 2.5 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely bromocriptine (as bromocriptine mesilate) 10 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely bromocriptine (as bromocriptine mesilate) 1 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely bromocriptine (as bromocriptine mesilate) 5 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely cabergoline 500 microgram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely benserazide 12.5 milligram and levodopa 50 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely benserazide 25 milligram and levodopa 100 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely benserazide 50 milligram and levodopa 200 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing procyclidine in oral dose form (medicinal product form) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing biperiden in parenteral dose form (medicinal product form) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing procyclidine in parenteral dose form (medicinal product form) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing apomorphine in parenteral dose form (medicinal product form) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing benzatropine in parenteral dose form (medicinal product form) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing benzatropine in oral dose form (medicinal product form) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing biperiden in oral dose form (medicinal product form) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing carbidopa and levodopa Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing carbidopa and entacapone and levodopa Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely carbidopa 12.5 milligram and entacapone 200 milligram and levodopa 50 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 100 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely carbidopa 37.5 milligram and entacapone 200 milligram and levodopa 150 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely rasagiline 1 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing benserazide and levodopa Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing rasagiline Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing benserazide Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely rasagiline 500 microgram/1 each conventional release oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing rotigotine Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely carbidopa 25 milligram and entacapone 200 milligram and levodopa 200 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ropinirole hydrochloride 500 microgram/1 each conventional release oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ropinirole hydrochloride 3 milligram/1 each conventional release oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole dihydrochloride 1.5 milligram/1 each conventional release oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely selegiline hydrochloride 5 milligram/1 each conventional release oral capsule Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely amantadine hydrochloride 100 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely carbidopa 25 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely tolcapone 100 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely tolcapone 200 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely benzatropine mesilate 500 microgram/1 each conventional release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole dihydrochloride 500 microgram/1 each conventional release oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely orphenadrine citrate 100 milligram/1 each conventional release oral tablet Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Benzatropine 1mg tablets Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ropinirole hydrochloride 4 milligram/1 each conventional release oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing carbidopa Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ropinirole (as ropinirole hydrochloride) 4 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ropinirole (as ropinirole hydrochloride) 2 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ropinirole (as ropinirole hydrochloride) 8 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing procyclidine Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing amantadine Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing metixene (medicinal product) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing biperiden Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole dihydrochloride 3 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole dihydrochloride 4.5 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole dihydrochloride 375 microgram/1 each prolonged-release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole dihydrochloride 1.5 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole dihydrochloride 750 microgram/1 each prolonged-release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely bromocriptine 800 microgram/1 each conventional release oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole dihydrochloride 125 microgram/1 each conventional release oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole dihydrochloride 250 microgram/1 each conventional release oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pramipexole dihydrochloride 750 microgram/1 each conventional release oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing benzatropine Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Product containing carbidopa and levodopa in oral dose form (medicinal product form) Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Pergolide Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Pramipexole Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Procyclidine Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Rasagiline Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Ropinirole Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Rotigotine Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Safinamide Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Tolcapone Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier
Trihexyphenidyl Plays role True Antiparkinson therapeutic role Inferred relationship Existential restriction modifier

Page 1 of 4 Next End

This concept is not in any reference sets

Back to Start